BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Nurturing Hacks: Shrewdness from Experienced Mothers and Fathers - 2Setbacks in Texas and elsewhere put Republicans' redistricting hopes in doubt as key deadlines loom
- 3More than 800 flights canceled as FAA cuts traffic at 40 major airports. Here's what to know.
- 4Share your number one city visit transport that leaves a mark on the world wake up!
- 5Extravagance SUVs for Seniors: Solace, Innovation, and Security
- Most loved VR Game for Wellness: Which Keeps You Dynamic?
- Pope Leo XIV calls for urgent climate action and says God’s creation is 'crying out'
- Finding Your Motivation: Moves toward a Satisfying Life
- NASA unveils close-up pictures of the comet popping by from another star
- From Modesty to Administration: Self-improvement in Interactive abilities
- Instructions to Clean and Really focus on Your Lab Precious stone
- The Main 20 Gaming Control center Ever
- Vote in favor of your Number one Sort of Cap
- Audits of 6 American Busssiness Class Flights
